Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects - Test2 - elhamkhani - TriplyDB

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

http://www.wikidata.org/entity/Q24641829

about

The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis Recent developments and future prospects in the treatment of visceral leishmaniasis Antituberculosis therapy for 2012 and beyond Nitroimidazoles for the treatment of TB: past, present and future Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis Molecular insights into the binding of coenzyme F420 to the conserved protein Rv1155 from Mycobacterium tuberculosis.Insights into the pharmacokinetic properties of antitubercular drugs.The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery.Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver.PA-824 exhibits time-dependent activity in a murine model of tuberculosis.Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824.Drug-resistant tuberculosis: emerging treatment options.Current development and future prospects in chemotherapy of tuberculosis Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis Phase II dose-ranging trial of the early bactericidal activity of PA-824 New drugs and regimens for treatment of TB.Design and Synthesis of Molecular Scaffolds with Anti-infective Activity.Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects.Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects.Emerging drugs for the treatment of tuberculosis.The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies.Tuberculosis drugs: new candidates and how to find more.New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.Antituberculosis drug research: a critical overview.Prospects for new antibiotics: a molecule-centered perspective.Resistance in tuberculosis: what do we know and where can we go?Investigational drugs for visceral leishmaniasis.The anti-tuberculosis agents under development and the challenges ahead.Drug Resistance Mechanisms in Mycobacterium tuberculosis.Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities.Nitroimidazooxazoles(#) Part xxiv, Search for Antileishmanial Agents: 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles as Potential Antileishmanial Agents.A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro.

P2860

Q24633734-12D69E62-018B-43A0-83AA-D3E954B0BB13 Q26740563-4290E472-74A1-40AF-865A-50A2947A1312 Q26829101-8ED97E4D-12D6-402E-89BB-82B96A87FD6E Q26849554-E0ADAE03-49FC-4C3E-8E84-470FB339F762 Q28478920-2F53EB03-98C0-446B-A658-E014E65B3B3F Q28478966-EF2E7674-D6E5-44FA-9C59-EB707E36C6B9 Q28542435-5488E42D-5616-401D-979B-12683AACA5F7 Q29568187-4B71C8B0-BA7A-4316-9B81-5D4F8B049978 Q30251497-67F2B51E-D0A1-41DF-8907-5B09270A2804 Q30447200-497E7D41-1147-4F1D-837A-11609CB1D112 Q33768799-6862CDE4-E154-4503-9842-D6D9D0665D7A Q34045233-B0ECBD5A-CF2B-48D1-B869-90B60C6CE739 Q34113517-36AA0024-A440-4F27-B4BD-7AF29DB60026 Q34410451-838D5119-ACB5-4B5B-AFCA-ED228CCDFDEC Q34449746-07D92975-2ECC-4C19-A8D9-05D408AA2CEB Q34483632-15AF3CAE-4CDE-4C91-BF6A-CAC99002AA24 Q34609996-E71A23B3-ADA8-422B-BE3A-8B42A0AF01B6 Q35598383-462A3F0C-970C-49E5-851C-818F3388FE57 Q35683967-63189FC9-3489-45CE-9222-491B12CF314B Q35705874-56875C3A-6A9D-4316-9D13-2B3104D1A88E Q35960987-E8DF9C71-43FB-4648-A915-6A645F75BF30 Q36018781-23B166B3-71CB-4531-AB4A-2566ADF5ECAD Q36825354-B2DD7E1E-8CE1-4D37-8ACB-26420E186F4A Q36972421-5F1B6DA3-9802-4054-B5FB-61004F20B468 Q37036499-18230E24-D194-4F51-BA89-3445B122B8C1 Q37263381-F774ACB6-EE9D-4B4A-B3C3-868F89E215CF Q37333140-D499152D-9879-4238-8371-62AB98058D4B Q37792105-686D17C4-1ADE-44D7-843D-D77DC38FBDFF Q37855837-03D3127E-1842-4FE2-8CC1-4B2A98D83BC7 Q37894691-038007C7-21EF-4499-9424-8D1A0B7B1BFC Q37996998-8621038E-8134-453B-8D17-9551D111FC89 Q38012651-AAF934D6-382A-43E0-A545-6EF7AFE002FE Q38113689-1B97A306-C1DF-48B9-87C8-47CFEF589655 Q38124261-76A77042-894B-463F-9379-67CB6A47B803 Q38269581-354DB0F9-716E-4FFD-BA34-3EE29F0E6DC1 Q38617197-ECDB4C5E-01D1-4E91-949D-7222C86AFB9E Q38792870-9A1FD011-01E9-402A-B70C-A1228CE96D96 Q38875308-E2F87D5D-BB85-4CBB-B4E5-CEC89B11DAED Q39141424-025B5A50-F553-4E1F-8D3A-B92936A664A2 Q39492522-A0C8BB93-4B10-4E6A-9FE6-D88EC33B5B8F

P2860

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

http://www.wikidata.org/entity/Q24641829

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

@ast

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

@en

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

@nl

type

label

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

@ast

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

@en

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

@nl

prefLabel

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

@ast

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

@en

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

@nl

P1433

Q24641829-7D666735-77C4-4A9E-823C-39AF8EAE48D9

P1476

Q24641829-DA7A51CE-5819-4328-B02E-AF9C30F49651

P2093

Q24641829-15D0A36C-16F7-4755-9C76-F5DE7E26A690

Q24641829-1AE1BA98-92FE-44F5-8CF1-58A457BFE282

Q24641829-35EAEE30-F906-4211-B083-6BC11C05E3B0

Q24641829-5271B440-90AC-4EEC-BCCF-5DFF8D6600D5

Q24641829-A0C63D35-F886-4EA8-8F81-211590A8C004

P2860

Q24641829-0D6A5990-D168-47C7-BAF7-D0A5443B1C6B

Q24641829-22EE1FCC-961B-4518-B6E3-7C5272930C13

Q24641829-58B106D9-C712-42DF-BA0B-203FBB158E75

Q24641829-6959BDA3-163A-445B-8945-AA944503141B

Q24641829-6AA6C99C-9E2B-45F9-96A2-78A2E930E473

Q24641829-704FC115-ABCB-423E-B949-EB6F3722F72F

Q24641829-8751344E-7432-475E-9CF4-561724BE6AC2

Q24641829-9F21FFC9-2DFB-46A0-B118-CBDD2ECA5A84

Q24641829-A8E7393A-543C-4C25-A630-EEF619C32D88

Q24641829-D7A34A24-FA79-49C4-98AB-2DD63A8583F2

P304

Q24641829-8786A225-8768-4429-9C9C-2114257F3FB1

P31

Q24641829-DADB5D32-852E-4305-99C7-03DE20394ECA

P356

Q24641829-BBA2A07B-52B3-464E-AC2A-B2F25F2AAB25

P407

Q24641829-54B77B83-8714-42D7-B469-CCFF6E64F2F2

P433

Q24641829-9C98253A-7B92-4CD3-8DAE-7159E1BEB98F

P478

Q24641829-1E8AEE7A-518D-436B-9CBD-C5546A4C0D10

P577

Q24641829-D5D7E018-9DC4-4AA7-835D-AB452B690B3B

P698

Q24641829-BC91F42E-C7DF-4EAE-9E7A-7137C6ED580B

P921

Q24641829-A1B3EB3E-87AA-41CF-8D28-A9FE41C232A3

Q24641829-EB97379C-FA52-45A2-B286-D28DD458A68F

P932

Q24641829-D89EF2A5-7F7F-4840-8429-12C07C9AA601

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

@en

P2093

Ann M Ginsberg

http://www.w3.org/2001/XMLSchema#string

Doris J Rouse

http://www.w3.org/2001/XMLSchema#string

Karl D Whitney

http://www.w3.org/2001/XMLSchema#string

Martino W Laurenzi

http://www.w3.org/2001/XMLSchema#string

Melvin K Spigelman

http://www.w3.org/2001/XMLSchema#string

P2860

Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

Global incidence of multidrug-resistant tuberculosis

In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis

Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.

Mycobacterium leprae is naturally resistant to PA-824

P304

3720-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00106-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19528280

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

pharmacokinetics

P932

2737845

http://www.w3.org/2001/XMLSchema#string